$2.85
0.103.64%
Last update: Nov 10, 5:49 PM
Sunshine Biopharma Inc
SBFMNASDAQ
Sunshine Biopharma fell 84.0% from $17.20 to $2.75, behind the S&P 500's +10.0%. Its worst day was May 15 (−39.5%), and its low came Oct 22 at $0.17.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.90 missed the $-1.20 estimate on $9.4M revenue (est. $12.0M).
−2.4% · S&P 500 0.0%
EPS of $-4.60 missed the $-2.70 estimate on $8.6M revenue (est. $10.0M).
Story events cover the past 12 months · Times ET
+9.4% · S&P 500 +0.5%
EPS of $-2.50 missed the $-1.60 estimate on $8.1M revenue (est. $9.2M).
−28.9% · S&P 500 +0.8%
EPS of $-1.15 beat the $-1.20 estimate on $9.3M revenue (est. $8.6M).
−2.6% · S&P 500 −0.5%
Sunshine Biopharma closed at its lowest level of the year, 99.0% below where the year started.
−22.5% · S&P 500 −1.2%
Where it ended: a close of $2.75 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-3.40, revenue est. $9.6M).
Nothing in the past 12 months.
All SBFM analyst actionsNothing in the past 12 months.
All SBFM dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SBFM and SPY from Benzinga historical bars. Not investment advice.
